Article
Immunology
Rosario Hervas-Salcedo, Maria Fernandez-Garcia, Miriam Hernando-Rodriguez, Cristian Suarez-Cabrera, Juan A. Bueren, Rosa M. Yanez
Summary: Previous clinical trials have shown that mesenchymal stromal cells (MSCs) can modulate graft versus host disease (GvHD) after allogeneic hematopoietic transplantation. Adipose tissue derived-human MSCs (Ad-MSCs) were engineered to express CXCR4 and IL-10, resulting in CXCR4-IL10-MSCs with enhanced migration and immunomodulatory properties. In vitro and in vivo studies demonstrated the improved therapeutic effects of CXCR4-IL10-MSCs, suggesting their potential as a new generation of MSCs for GvHD treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Kilian Kelly, John E. J. Rasko
Summary: GvHD is a life-threatening complication of hematopoietic stem cell transplantation, often requiring high-dose corticosteroid treatment. MSCs show promise as a potential therapy due to their immunosuppressive and immunoregulatory effects, but their efficacy may be influenced by donor variability and manufacturing processes.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Neurosciences
Francesca Pischiutta, Enrico Caruso, Helena Cavaleiro, Antonio J. Salgado, David J. Loane, Elisa R. Zanier
Summary: Traumatic brain injury (TBI) patients require better neuroprotective/neuroreparative strategies. Mesenchymal stromal cells (MSCs) have shown promise in neuroprotection through paracrine mechanisms. Immunomodulation by MSC-derived secretome is a key mechanism for their therapeutic effects. Secretome promotes tissue repair and neurological recovery, but excessive neuroinflammatory response can worsen TBI.
EXPERIMENTAL NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Andrei Mircea Vacaru, Ana-Maria Mazilu, Madalina Dumitrescu, Ioana Madalina Fenyo, Anca Violeta Gafencu, Ana-Maria Vacaru
Summary: This study found that treatment with FasL-overexpressing MSC can improve GvHD and increase survival in mice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Olle Ringden, Guido Moll, Britt Gustafsson, Behnam Sadeghi
Summary: This article summarizes the authors' more than 20 years of scientific experience in the clinical use of MSCs and DSCs in different clinical settings. MSCs and DSCs have significant effects on the immune system and coagulation, and show potential clinical efficacy in conditions such as acute GvHD, ARDS, and hemorrhages.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Piotr Poplawski, Weronika Zarychta-Wisniewska, Anna Burdzinska, Joanna Boguslawska, Anna Adamiok-Ostrowska, Karolina Hanusek, Beata Rybicka, Alex Bialas, Helena Kossowska, Roksana Iwanicka-Rokicka, Marta Koblowska, Leszek Paczek, Agnieszka Piekielko-Witkowska
Summary: In this study, it was found that advanced RCC cells secrete AREG, FN1, and HA to induce MSCs migration, and MSCs' gene expression is reprogrammed to facilitate their migration. The identified components of RCC secretome may serve as potential therapeutic targets.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Pharmacology & Pharmacy
Hui Li, Qi Liu, Xiaofeng Gao, Di Zhang, Shengjun Mao, Yongqian Jia
Summary: The study explored the potential of human umbilical mesenchymal stem cells transfected with IFN-γ gene and found that this treatment significantly reduced the incidence and severity of GVHD in vivo, providing a significant survival benefit.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Immunology
Thomas Krueger, Rebekka Wehner, Maik Herbig, Martin Kraeter, Michael Kramer, Jan Moritz Middeke, Friedrich Stoelzel, Catrin List, Katharina Egger-Heidrich, Raphael Teipel, Uta Oelschlaegel, Martin Wermke, Helena Jambor, Manja Wobus, Johannes Schetelig, Korinna Joehrens, Torsten Tonn, Julien Subburayalu, Marc Schmitz, Martin Bornhauser, Malte von Bonin
Summary: Functional impairment of the bone marrow niche, particularly a decrease in mesenchymal stromal cells (MSCs), is associated with cytopenia and graft failure after hematopoietic cell transplantation. Acute graft-versus-host disease (aGvHD) is shown to significantly reduce MSC numbers, and this reduction can be observed before clinical onset of aGvHD. The different phenotypic and functional characteristics of MSCs depending on the occurrence of aGvHD suggest that they may contribute to alloreactivity after transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Shu Hui Neo, Zhisheng Her, Rashidah Othman, Ching Ann Tee, Li Ching Ong, Yuehua Wang, Irwin Tan, Jaylen Tan, Yanmeng Yang, Zheng Yang, Qingfeng Chen, Laurie A. Boyer
Summary: Culturing MSCs at high confluency enhances their immunomodulatory functions, inhibiting T cell proliferation and pro-inflammatory cytokine secretion, leading to improved therapeutic efficacy in GVHD mouse model.
STEM CELL RESEARCH & THERAPY
(2023)
Article
Cell & Tissue Engineering
Oliver Treacy, Kevin Lynch, Nick Murphy, Xizhe Chen, Ellen Donohoe, Aoife Canning, Paul Lohan, Georgina Shaw, Gerry Fahy, Aideen E. Ryan, Thomas Ritter
Summary: The study showed that low-dose subconjunctival injection of allogeneic MSCs effectively promoted corneal allograft survival, indicating a potential for improving future MSC immunotherapies for preventing corneal allograft rejection.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Zhihong Xu, Lulu Lin, Yuxuan Fan, Celine Huselstein, Natalia De Isla, Xiaohua He, Yun Chen, Yinping Li
Summary: Consecutive hypoxic culture enhances proliferation and decreases senescence of UC-MSCs, as well as promotes the secretion of immunomodulatory cytokines, leading to mitigation of lung inflammation in ALI models. Both Nor-CM and Hypo-CM can effectively limit lung inflammation, promote efferocytosis, and modulate anti-inflammatory polarization of lung macrophages, with the effects of Hypo-CM being more potent.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Lucas Eduardo Botelho de Souza, Fernanda Ursoli Ferreira, Carolina Hassibe Thome, Heloisa Brand, Maristela Delgado Orellana, Vitor Marcel Faca, Aparecida Maria Fontes, Dimas Tadeu Covas
Summary: Melanoma cells have the capability to activate an EMT-like program and acquire metastatic traits through distinct pathways induced by MSCs' secretome, both in mouse and human cells.
Review
Cell Biology
Luise Mueller, Antje Tunger, Manja Wobus, Malte von Bonin, Russell Towers, Martin Bornhaeuser, Francesco Dazzi, Rebekka Wehner, Marc Schmitz
Summary: Mesenchymal stromal cells (MSCs) have the ability to regulate and inhibit the function of immune cells, playing a crucial role in the pathogenesis of inflammatory disorders and showing promise in the treatment of conditions such as acute graft-versus-host disease, graft rejection, and autoimmune diseases.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Dragan Primorac, Martin Cemerin, Vid Matisic, Vilim Molnar, Marko Strbad, Lenart Girandon, Lucija Zenic, Miomir Knezevic, Stephen Minger, Denis Polancec
Summary: The COVID-19 pandemic has had a significant impact globally and the overaggressive immune reaction in response to the virus can lead to ARDS. Mesenchymal stromal cell therapy presents a potential treatment option for severe patients.
Review
Immunology
Ayman F. Refaie, Batoul L. Elbassiouny, Malgorzata Kloc, Omaima M. Sabek, Sherry M. Khater, Amani M. Ismail, Rania H. Mohamed, Mohamed A. Ghoneim
Summary: MSC-based therapy for T1DM shows promise, but there are conflicting views on their immunological profile. Research focuses on understanding the mechanisms of their immunomodulatory functions and exploring ways to enhance their effects.
FRONTIERS IN IMMUNOLOGY
(2021)